Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genasense Accelerated Approval Not Supported Due To Failed Outcomes Data

Executive Summary

Accelerated approval based on response rate is not appropriate for Genta's Genasense given the Bcl-2 inhibitor's failure to show a benefit on clinical outcomes in a randomized Phase III trial, FDA and members of its Oncologic Drugs Advisory Committee said during a Sept. 6 meeting
Advertisement

Related Content

FDA Approves Cephalon’s CLL Therapy Treanda With Broad Label
FDA Approves Cephalon’s CLL Therapy Treanda With Broad Label
FDA Advisory Panels Off To Slow Start In 2007 After Role Change In 2006
FDA Advisory Panels Off To Slow Start In 2007 After Role Change In 2006
Genasense panel questioned
Genasense panel questioned
Genasense Progression-Free Survival Data Do Not Show “Real Effect,” Cmte.
Genasense Progression-Free Survival Data Do Not Show “Real Effect,” Cmte.
Advertisement
UsernamePublicRestriction

Register

PS047559

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel